Research article summary (published 29 Sep 2009):

American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Author information

Author/s: Temin, Sarah (S); American Society of Clinical Oncology;

Affiliation: American Society of Clinical Oncology, Cancer Policy and Clinical Affairs Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314, USA.

Journal and publication information

Publication Type: Journal Article; Practice Guideline

Journal: Gynecologic oncology (Gynecol Oncol), published in United States. (Language: eng)

Reference: 2009-Oct; vol 115 (issue 1) : pp 132-4

Dates: Created 2009/08/31; Completed 2009/09/07;

PMID: 19716939, status: MEDLINE (last retrieval date: 9/7/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Inhibitors - adverse effects; therapeutic use Breast Neoplasms - prevention & control Female

Fenretinide - adverse effects; therapeutic use Humans Raloxifene - adverse effects; therapeutic use Tamoxifen - adverse effects; therapeutic use

Associated Chemicals: Aromatase Inhibitors (0) ; Tamoxifen (10540-29-1) ; Fenretinide (65646-68-6) ; Raloxifene (84449-90-1)

Related articles

These are the highest related articles currently in the database:

• Pharmacological prevention of breast cancer: quo vadis? 29 Nov 2003
• Breast cancer chemoprevention: current clinical practice and future direction. 30 Oct 2001
• Chemoprevention of breast cancer in postmenopausal women. 30 Dec 2004
• Chemoprevention of breast cancer. 30 Dec 2007
• Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. 30 Dec 2001
• Effect of SERMs on the uterus and menopausal symptoms. 30 Aug 1999
• Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint. 30 Oct 2007
• Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. 30 Oct 2007
• A STAR is born. 30 Jul 2006
• Chemoprevention of breast cancer. 27 Apr 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.